Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Artemis Resources Limited

ABN

80 107 051 749

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Class of +securities issued or to be issued

Fully paid ordinary shares (Shares).

- 2 Number of *+*securities issued or to be issued (if known) or maximum number which may be issued
- Principal of terms the 3 +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

4,000,000
 2,710,355

Same terms as existing shares

<sup>+</sup> See chapter 19 for defined terms.

Do the +securities rank equally 4 in all respects from the date of Yes, rank equally with existing quoted allotment with an existing <sup>+</sup>class Shares. of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 1,000,000 at 14 cents per Share, 1,000,000 Issue price or consideration 5 1. at 13 cents per Share, 1,000,000 at 12 cents per share and 1,000,000 at 11 cents per share Issued at a deemed price of 15.83 cents 2. per share Purpose of the issue Exercise of options 6 1. (If issued as consideration for Issued in settlement of instalment of 2. the acquisition of assets, clearly convertible note repayment in amount identify those assets) of US\$240,000 6a Is the entity an +eligible entity Yes that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *+securities* the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 29 November 2017 resolution under rule 7.1A was passed Number of +securities issued 6c 2,710,355 without security holder approval under rule 7.1

<sup>+</sup> See chapter 19 for defined terms.

- 6d Number of \*securities issued with security holder approval under rule 7.1A
- 6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 <sup>+</sup>Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8

Nil.

4,000,000

N/A

N/A

Capacity under rule 7.1 – 15,872,299 securities Capacity under rule 7.1A – 19,848,341 securities

See Appendix 1

1 May 2018

Number+Class633,293,770ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9	Number and <sup>+</sup> class of all
	<sup>+</sup> securities not quoted on ASX
	(including the securities in
	section 2 if applicable)

Number	+Class
13,000,000	Director employee rights expiry 30 June 2019
2,000,000	Employee performance rights expiry 30 June 2019
6,000,000	Unlisted options exercisable at 44 cents on or before 30 June 2020
5,439,858	Unlisted options exercisable at 45.38 cents on or before 31 January 2021
11,250,000	Unlisted options exercisable at 25 cents on or before 6 February 2019

Dividend policy (in the case of a Not applicable. 10 trust, distribution policy) on the increased capital (interests)

# Part 2 - Bonus issue or pro rata issue

holder approval Is security 11 required? Is the issue renounceable or non-12 renounceable? Ratio in which the \*securities 13 will be offered <sup>+</sup>Class of <sup>+</sup>securities to which the 14 offer relates

<sup>+</sup> See chapter 19 for defined terms.

15       "Record date to determine entitlements         16       Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements in relation to fractions         18       Names of countries in which the entity has "security holders who will not be sent new issue documents         New: Sociary holders must be told how their entitlements are to be dath with.         Cross reference: rule 77.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriting fee or commission         21       Amount of any underwriting fee or commission payable to the issue         22       Names of any brokers to the lasse         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of "security holders" approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled			
registers (or subregisters) be aggregated for calculating entitlements?         17       Policy for deciding entitlements in relation to fractions         18       Names of countries in which the entity has "security holders who will not be sent new issue documents         Not: Security holders must be told how their entitlements are to be dath with.         Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of "security holders" approval, the date of the meeting         25       If the issue is contingent on "security holders" approval, the date of the meeting         26       Date entilement and acceptance for madu prospectus or Product Disclosure Statement will be sent	15		
<ul> <li>in relation to fractions</li> <li>18 Names of countries in which the entity has 'security holders who will not be sent new issue documents</li> <li>Note: Security holders must be told how their entitlements are to be dealt with.</li> <li>Cross reference: rule 7.7.</li> <li>19 Closing date for receipt of acceptances or renunciations</li> <li>20 Names of any underwriters</li> <li>21 Amount of any underwriting fee or commission</li> <li>22 Names of any brokers to the issue</li> <li>23 Fee or commission payable to the broker to the issue</li> <li>24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of "security holders"</li> <li>25 If the issue is contingent on 'security holders' approval, the date of the meeting</li> <li>26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent</li> </ul>	16	registers (or subregisters) be aggregated for calculating	
<ul> <li>in relation to fractions</li> <li>18 Names of countries in which the entity has 'security holders who will not be sent new issue documents</li> <li>Note: Security holders must be told how their entitlements are to be dealt with.</li> <li>Cross reference: rule 77.</li> <li>19 Closing date for receipt of acceptances or renunciations</li> <li>20 Names of any underwriters</li> <li>21 Amount of any underwriting fee or commission</li> <li>22 Names of any brokers to the issue</li> <li>23 Fee or commission payable to the broker to the issue</li> <li>24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of "security holders"</li> <li>25 If the issue is contingent on 'security holders' approval, the date of the meeting</li> <li>26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent</li> </ul>			
entity has *security holders who will not be sent new issue documents         Note: Security holders must be told how their entitlements are to be dealt with.         Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent	17		
entitlements are to be dealt with.         Cross reference: rule 7.7.         19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent	18	entity has <sup>+</sup> security holders who will not be sent new issue documents	
19       Closing date for receipt of acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent			
acceptances or renunciations         20       Names of any underwriters         21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent		Cross reference: rule 7.7.	
21       Amount of any underwriting fee or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent	19	ē .	
or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent	20	Names of any underwriters	
or commission         22       Names of any brokers to the issue         23       Fee or commission payable to the broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent			
<ul> <li>issue</li> <li>23 Fee or commission payable to the broker to the issue</li> <li>24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders</li> <li>25 If the issue is contingent on *security holders' approval, the date of the meeting</li> <li>26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent</li> </ul>	21		
broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent	22	-	
broker to the issue         24       Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders         25       If the issue is contingent on *security holders' approval, the date of the meeting         26       Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent			
<ul> <li>payable to brokers who lodge acceptances or renunciations on behalf of *security holders</li> <li>25 If the issue is contingent on *security holders' approval, the date of the meeting</li> <li>26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent</li> </ul>	23		
<ul> <li>*security holders' approval, the date of the meeting</li> <li>26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent</li> </ul>	24	payable to brokers who lodge acceptances or renunciations on	
form and prospectus or Product Disclosure Statement will be sent	25	*security holders' approval, the	
	26	form and prospectus or Product Disclosure Statement will be sent	

<sup>+</sup> See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?	
31	How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do <sup>+</sup> security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
- (a) Securities described in Part 1
- (b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a) Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

If the \*securities are \*equity securities, the names of the 20 largest holders of the additional \*securities, and the number and percentage of additional \*securities held by those holders

<sup>+</sup> See chapter 19 for defined terms.

36	+ 1 1, 5	T the *securities are *equity securities securities setting out the number of - 1,000 001 - 5,000 0001 - 10,000 0,001 - 100,000 00,001 and over			
37	A	copy of any trust deed for the addit	ional	+securities	
Entit	ies tha	t have ticked box 34(b)			
38	Number sought	r of securities for which <sup>+</sup> quotatio	n is		
39	Class o sought	f <sup>+</sup> securities for which quotation	n is		
40	from th	<sup>+</sup> securities rank equally in all resp e date of allotment with an exis f quoted <sup>+</sup> securities?			
	<ul> <li>please s</li> <li>the c</li> <li>the c</li> <li>next</li> <li>distr</li> <li>the c</li> <li>other</li> </ul>	dditional securities do not rank equ tate: late from which they do extent to which they participate for dividend, (in the case of a t ibution) or interest payment extent to which they do not rank equ r than in relation to the next divid ibution or interest payment	the rust, ally,		
41	Reason	for request for quotation now			
•		a the case of restricted securities, end of restriction p	eriod		
		d upon conversion of another secu dentify that other security)	rity,		
				Number	+Class

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in clause 38)

Number	+Class

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:		Date:3/5/18
-	(Company secretary)	
Print name:	Guy Robertson	

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1 Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities - Part 1 –

Introduced 01/08/12

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	280,419,589	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note: <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	2,244,576 – exercise of options $3/5/17$ 500,000 – exercise of options $15/5/17$ 300,000 – exercise of options $22/5/17$ 777,084 – exercise of options $29/5/17$ 20,000,000 – $29/5/17$ 3,862,011 – $2/6/17$ exercise of options 558,916 – $9/6/17$ exercise of options 1,771,764 – $23/6/17$ exercise of options 800,000 – $29/6/17$ exercise of options 20,157,000 – $19/7/17$ exercise of options 7,895,451 – $28/7/17$ exercise of options 13,685,632 – $4/8/17$ exercise of options 2,132,750 – $9/8/17$ exercise of options 1,773,250 – $17/8/17$ exercise of options 1,773,250 – $17/8/17$ exercise of options 2,85,000 – $1/9/17$ exercise of options 32,000,000 – approved EGM $8/9/17$ 1,542,500 – $13/9/17$ exercise of options 9,262,901 – $22/9/17$ exercise of options	

<sup>+</sup> See chapter 19 for defined terms.

	16,570,326 – 29/9/17 exercise of options 4,400,000 – 31/10/17 exercise of options
	15,959,803 – share issue approved AGM 29/11/17
	45,000,000 – share issue approved AGM 29/11/17
	5,000,000 – share issue approved AGM 29/11/17
	15,000,000 – share issue approved AGM 29/11/17
	23,696,682 – share issue approved AGM 29/11/17
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	0
"A"	548,483,415

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	82,272,512	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
<i>Insert</i> number of equity securities issued or	2,000,000 – 15/11/17 Unlisted Options	
agreed to be issued in that 12 month period <i>not counting</i> those issued:	25,000,000 Shares – 8/12/17	
Under an exception in rule 7.2	2,000,000 8/12/17 Unlisted Options	
Under rule 7.1A	8,000,000 Shares – 31/1/18	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	5,439,858 – 31/1/18 Unlisted options	
	10,000,000 – 5/2/18 shares	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded patients ordinany</li> </ul>	11,250,000 – 5/2/18 unlisted options	
<ul> <li>specifically excluded – not just ordinary securities</li> <li>Include here (if applicable ) the</li> </ul>	2,710,355 – 1/5/18 Share Issue	

<sup>+</sup> See chapter 19 for defined terms.

Stop A: Subtract "C" from ["A" x "B"] to calculate remaining		
"C"	66,400,213	
<ul> <li>securities the subject of the Appendix</li> <li>3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

# Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15	82,272,512
Note: number must be same as shown in Step 2	
Subtract "C"	66,400,213
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	15,872,299
	[Note: this is the remaining placement capacity under rule 7.1]

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	548,483,415	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	54,848,341	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	35,000,000 shares 5/2/18 & 6/2/18	

<sup>+</sup> See chapter 19 for defined terms.

<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"E"	35,000,000

# Step 4: Subtract "E" from ["A" x "D"] to calculate remaining<br/>placement capacity under rule 7.1A"A" x 0.1054,848,341Note: number must be same as shown in<br/>Step 254,848,341Subtract "E"35,000,000Note: number must be same as shown in<br/>Step 335,000,000Total ["A" x 0.10] - "E"19,848,341Note: this is the remaining placement<br/>capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.